Edwards Lifesciences Corp (EW)vsLucid Diagnostics Inc (LUCD)
EW
Edwards Lifesciences Corp
$85.27
-1.30%
HEALTHCARE · Cap: $49.03B
LUCD
Lucid Diagnostics Inc
$0.54
-10.38%
HEALTHCARE · Cap: $121.83M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 119501% more annual revenue ($6.51B vs $5.45M). EW leads profitability with a 15.4% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
LUCD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.6%
Fair Value
$252.59
Current Price
$85.27
$167.32 discount
Intrinsic value data unavailable for LUCD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Revenue surging 26.7% year-over-year
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Trading at 9.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : LUCD
The strongest argument for LUCD centers on Revenue Growth. Revenue growth of 26.7% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 50.7x leaves little room for execution misses.
Bear Case : LUCD
The primary concerns for LUCD are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.28 is elevated, increasing financial risk.
Key Dynamics to Monitor
EW profiles as a mature stock while LUCD is a growth play — different risk/reward profiles.
LUCD carries more volatility with a beta of 1.12 — expect wider price swings.
LUCD is growing revenue faster at 26.7% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 24/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Lucid Diagnostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Lucid Diagnostics Inc. is a commercial stage medical diagnostic technology company. The company is headquartered in New York, New York.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?